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Abstract
Malaria in pregnancy (MiP) is associated with increased risks of maternal and foetal complications. The WHO recommends a
package of interventions including intermittent preventive treatment (IPT) with sulphadoxine-pyrimethamine (SP),
insecticide-treated nets and effective case management. However, with increasing SP resistance, the effectiveness of SP-IPT
has been questioned. Intermittent screening and treatment (IST) has recently been shown in Ghana to be as efficacious as
SP-IPT. This study investigates two important requirements for effective delivery of IST and SP-IPT: antenatal care (ANC)
provider knowledge, and acceptance of the different strategies. Structured interviews with 134 ANC providers at 67 public
health facilities in Ashanti Region, Ghana collected information on knowledge of the risks and preventative and curative
interventions against MiP. Composite indicators of knowledge of SP-IPT, and case management of MiP were developed. Log
binomial regression of predictors of provider knowledge was explored. Qualitative data were collected through in-depth
interviews with fourteen ANC providers with some knowledge of IST to gain an indication of the factors influencing
acceptance of the IST approach. 88.1% of providers knew all elements of the SP-IPT policy, compared to 20.1% and 41.8%
who knew the treatment policy for malaria in the first or second/third trimesters, respectively. Workshop attendance was a
univariate predictor of each knowledge indicator. Qualitative findings suggest preference for prevention over cure, and
increased workload may be barriers to IST implementation. However, a change in strategy in the face of SP resistance is
likely to be supported; health of pregnant women is a strong motivation for ANC provider practice. If IST was to be
introduced as part of routine ANC activities, attention would need to be given to improving the knowledge and practices of
ANC staff in relation to appropriate treatment of MiP. Health worker support for any MiP intervention delivered through
ANC clinics is critical.
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Introduction
Plasmodium falciparum infection in pregnancy is associated with an
increased risk of maternal and foetal complications including
maternal anaemia and low birth weight [1,2]. The WHO has
recommended a package of interventions for preventing and
controlling malaria infection in pregnancy (MiP) in endemic areas,
which includes the early diagnosis and treatment of malaria, the
use of insecticide-treated nets (ITNs), and intermittent preventive
treatment during pregnancy (IPT) using sulphadoxine-pyrimeth-
amine (SP)[3].
However, in recent years resistance to SP has spread across sub-
Saharan Africa and thus the effectiveness of SP-IPT has been
questioned [4]. There are few anti-malarial drugs with plasma
half-life comparable to that of SP that could be used to replace SP
for IPT in areas with high SP resistance. Furthermore, there is
very limited information on the efficacy and safety during
pregnancy of alternative drugs [5]. A three-arm, open label,
individually-randomized trial was conducted in the Ashanti
Region of Ghana between February 2007 and November 2008
to investigate the efficacy of an alternative strategy: in two of the
arms, pregnant women were screened at scheduled antenatal care
(ANC) visits with a rapid diagnostic test (RDT) and those with a
positive result were treated with either artesunate-amodiaquine
(AS–AQ) or SP; women in the third arm received three doses of
SP-IPT at monthly intervals as per current national policy. The
alternative strategy, termed intermittent screening and treatment
(IST) was found to be non-inferior to SP-IPT in preventing
maternal anaemia and low birth weight [6].
Although IST appears to be a promising alternative to SP-IPT
for the control of malaria in pregnancy, translating efficacy from a
controlled trial setting to effectiveness under operational condi-
tions is challenging [7]. ANC attendance is very high in Ashanti
and many parts of sub-Saharan Africa, suggesting that delivery of
MiP interventions through this channel would achieve high
coverage. However, acceptability of the intervention by both
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users and providers is crucial, as well as issues of cost effectiveness
and capacity for implementation within the existing health system.
Despite the fact that 36 malaria-endemic countries have
adopted SP-IPTp as national policy [8], there is little literature
on the malaria-related knowledge of ANC staff or their practices
[9]. Existing perceptions, levels of knowledge and experience will
influence how a new strategy such as IST is accepted and adopted
by those who will be implementing it. For example, if a policy of
IST was to be implemented by ANC providers, it is assumed that
they would need to be trained in the use and interpretation of
RDTs. However, it may also be necessary to include additional
malaria in pregnancy topics such as prescribing and dispensing of
treatments, to support effective IST implementation.
An investigation of the perceptions and experiences of pregnant
women participating in the Ashanti IST trial showed that, overall,
the two strategies were equally acceptable and other factors such
as quality of care and health benefits for themselves and their
babies were perceived to be more important elements in affecting
the acceptability of ANC strategies [10].
Here we present the perspective of providers of ANC in the
public sector of Ashanti Region, in relation to their knowledge of
malaria in pregnancy and how it can be treated or prevented.
Methods
Ethics statement
Ethical approval for this study was granted by the Committee
on Human Research, Publications and Ethics, Kwame Nkrumah
University of Science and Technology, School of Medical
Sciences, Kumasi, Ghana and by the ethics committee of the
London School of Hygiene & Tropical Medicine. Written
informed consent was sought from all participants before the start
of all interviews (structured, or semi-structured), including
permission to use anonymous quotes. During transcription of
recorded key informant interviews, any names were replaced with
codes to ensure anonymity and digital recordings were deleted
once transcription was completed and quality approved.
Study area
The Ashanti Region of Ghana has 27 districts with a total
population of approximately 3.61 million. Ashanti is predomi-
nantly rural. Transmission of malaria is moderately high [11] and
occurs throughout the year with peaks during the rains from May-
October.
In 2008, 97.0% of women in the Ashanti Region received ANC
from a skilled provider at least once during their most recent
pregnancy [12]. All health facilities with an ANC clinic in the
study districts offer SP-IPT to pregnant women following the
Ministry of Health (MoH) guidelines which recommend three
doses of SP-IPT. According to the national guidelines, pregnant
women in their first trimester diagnosed with malaria should be
treated with quinine; those diagnosed with malaria in their second
or third trimester should be treated with AS-AQ. There is no
policy on screening pregnant women for malaria on attendance at
the ANC clinic. Counselling and testing for prevention of mother
to child transmission of HIV (PMTCT) is also part of core ANC
services in Ghana, with HIV prevalence amongst adults aged 15–
49 in Ghana at 1.8% [13]. All maternal health care, including
delivery has been free since July 2008, a policy implemented
through the National Health Insurance Scheme.
Health facility audit & health worker survey
The sampling scheme was designed to be representative of ANC
providers at the regional level. Based upon feasibility within
existing resources, 7 of 21 districts were randomly selected.
Although the number of districts in Ashanti had been recently
expanded, population data taking this into account were not
available at the time of the study. Therefore, selection was based
on the 21 districts as defined at the time of the 2000 census.
Kumasi Metropolitan district was purposively sampled because it
has a catchment population of approximately one-third of the
regional population. Ejisu-Juaben and Sekyere East districts were
excluded from the sampling frame to avoid facilities that had been
involved in the Ashanti IST trial as their ANC staff may not be
representative of the region as a whole. The remaining six districts
were randomly selected from the sampling frame of 18 districts
using population proportional to size.
All public and mission health facilities in these seven districts
(Adansi South, Afigya-Sekyere, Amansie West, Asante Akim
South, Bosomtwi/Atwima/Kwanhuma, Kumasi Metropolitan,
Offinso) that provide antenatal services were included.
Structured audits of each of the sampled health facilities were
conducted to investigate the personnel profile, laboratory and
dispensing services available at the facility, and availability of anti-
malarial drugs and rapid diagnostic tests in the facility and at the
ANC clinic.
All staff in the ANC clinic present on the day of the visit were
interviewed individually using a structured questionnaire, includ-
ing questions on health worker demographics, responsibilities in
the ANC clinic, recent training on malaria in pregnancy,
knowledge of the risks and consequences of malaria in pregnancy,
knowledge of the national policies for IPT and treatment of
uncomplicated malaria in pregnancy.
Facility audits and structured interviews with ANC staff were
conducted between August and December 2009. Data were
double-entered and validated in EpiData version 3.1 [14]. Stata
11.0 [15] was used for data processing and analysis. All analyses
adjusted for clustering at the health facility level.
Composite indicators were constructed based on full knowledge
of all components of current national policy for IPT and treatment
of malaria in pregnancy as follows: (i) full knowledge of IPTp was
defined as the proportion of ANC providers who knew the correct
drug, dose and timing, that use of SP-IPT is restricted in the ninth
month and that SP-IPT should be administered as directly-
observed therapy (DOT); (ii) full knowledge of treatment for
uncomplicated malaria in the first trimester of pregnancy was
defined as the proportion of ANC providers who knew the correct
drug (quinine), dose and duration; (iii) full knowledge of treatment
for uncomplicated malaria in the second and third trimesters of
pregnancy was defined as the proportion of ANC providers who
knew the correct drug (AS–AQ), dose and duration, including
restrictions on use of AS–AQ during first trimester.
Potential determinants of each of these three composite IPT and
treatment knowledge indicators were explored using log binomial
regression, adjusted for cluster effect at the facility level. Where
appropriate, univariate predictors with p-values of ,0.1 were
included in a multivariate model.
Key informant interviews
In-depth key informant interviews were conducted in January
and February 2009 in Ejisu-Juaben and Sekyere East districts with
a total of fourteen midwives and nursing assistants providing
routine ANC in the six facilities where the Ashanti IST trial took
place. As many providers as possible in each ANC clinic were
sought for interview and data collection continued until no new
themes were emerging. Interview topic guides were used, covering
provider perceptions and experience of the risks and consequences
of malaria in pregnancy, experience and opinions of implementing
IST & Malaria in Pregnancy: Provider Perspective
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SP-IPT, prior experience of conducting blood tests and their
opinions on the IST strategy under investigation at their health
facilities.
All interviews were conducted in English after checking that the
interviewee was comfortable expressing their opinions in this
language. With the informed consent of the participants, all
interviews were digitally recorded. Transcriptions were coded and
analysed by one of the authors (LSP) using NVivo version 8 [16].
A content analysis approach was used to identify themes based
around the providers’ opinions and experiences of malaria in
pregnancy [17]. The qualitative findings are used here to provide
an indication of provider acceptability of the IST approach and to
complement the quantitative findings of the health worker survey.
Results
Health facility audit
Sixty-seven ANC-providing health facilities in 7 districts of the
Ashanti Region were surveyed between August and December
2009. Of these 67 facilities, 77.6% (52) were government-run and
the remainder were mission facilities. Just over half were health
centres (50.8%, 34/67), 22.4% (15) were hospitals, 19.4% (13)
rural health clinics and 7.5% (5) community clinics. The median
number of new ANC registrants in 2008 across all facilities was
367 (interquartile range, IQR: 178–774) and the median total
number of ANC attendants in 2008 was 1136 (IQR: 434–2334). In
both cases, the data are highly skewed as the hospitals had
considerably higher ANC caseloads with a median of 1644 new
ANC registrants; two hospitals had over 5000 new registrants in
2008.
Almost all of the surveyed facilities had a drug dispensary
(91.0%, 61/67). The majority (70.1%, 47/67) kept SP in the ANC
for dispensing by midwives; of those that did not, 45.0% (9/20)
were health centres, 25.0% (5/20) rural health clinics, 15.0% (3/
20) hospitals and 15.0% (3/20) community clinics. Considerably
fewer facilities (25.4%, 17/67) kept AS–AQ available in the ANC
for dispensing by midwives; of those that did 64.7% (11/17) were
health centres, 23.5% (4/17) were rural health clinics and 11.8%
(2/17) were community clinics; none of the hospitals dispensed
AS–AQ in their ANC clinics (Table 1).
Just under half of the facilities surveyed had laboratory services
(47.8%, 32/67). Around 40% (27/67) had at least one functional
microscope and conducted microscopy for malaria parasites. Only
25.4% (17) of facilities currently use malaria RDTs and even fewer
(6.0%, 4/67) use RDTs in the ANC clinic (Table 1). Amongst
hospitals, 46.7% (7/15) used RDTs, compared to 17.7% of health
Table 1. Characteristics of the health facilities that participated in the study, according to level of facility.
Hospital
(N=15)
Health centre
(N=34)
Rural health
clinic (N=13)
Community
clinic
(N=5)
Total
(N=67)
n (%) n (%) n (%) n (%) n (%)
Dispensary in facility Yes 15 (100) 32 (94.1) 10 (76.9) 4 (80.0) 61 (91.0)
No 0 2 (5.9) 3 (23.1) 1 (20.0) 6 (9.0)
Drugs dispensed outside dispensary* No 4 (26.7) 21 (61.8) 7 (53.9) 3 (60.0) 35 (52.2)
Inpatients 8 (53.3) 2 (5.9) 0 0 10 (14.9)
Outpatients 2 (13.3) 2 (5.9) 4 (30.8) 1 (20.0) 9 (13.4)
ANC 9 (60.0) 13 (38.2) 5 (38.5) 1 (20.0) 28 (41.8)
SP kept in ANC for use by midwives Yes 12 (80.0) 25 (73.5) 8 (61.5) 2 (40.0) 47 (70.2)
No 3 (20.0) 9 (26.5) 5 (61.5) 3 (60.0) 20 (29.8)
AS–AQ kept in ANC for use by midwives Yes 0 11 (32.4) 4 (30.8) 2 (40.0) 17 (25.4)
No 15 (100) 23 (67.7) 9 (69.2) 3 (60.0) 50 (74.6)
Laboratory services provided Yes 15 (100) 11 (32.4) 3 (23.1) 3 (60.0) 32 (47.8)
No 0 23 (67.7) 10 (76.9) 2 (40.0) 35 (52.2)
Where laboratory services provided* On-site 15 (100) 8 (23.5) 3 (23.1) 1 (20.0) 27 (40.3)
Affiliated external lab 4 (26.7) 4 (11.8) 0 2 (40.0) 10 (14.9)
ANC 1 (6.7) 1 (2.9) 0 0 2 (3.0)
Functional microscope present Yes 15 (100) 8 (23.5) 3 (23.1) 1 (20.0) 27 (40.3)
No 0 26 (76.5) 10 (76.9) 4 (80.0) 40 (59.7)
Malaria blood films conducted Yes 15 (100) 8 (23.5) 3 (23.1) 1 (20.0) 27 (40.3)
No 0 26 (76.5) 10 (76.9) 4 (80.0) 40 (59.7)
Malaria RDTs conducted Yes 7 (46.7) 6 (17.7) 4 (30.8) 0 17 (25.4)
No 8 (53.3) 23 (67.7) 5 (38.5) 5 (100) 41 (61.2)
Don’t know 0 5 (14.7) 4 (30.8) 0 9 (13.4)
Where malaria RDTs used Laboratory 7 (46.7) 4 (11.8) 1 (7.7) 0 12 (17.9)
Outpatients 1 (6.7) 2 (5.9) 3 (23.1) 0 6 (9.0)
ANC 0 2 (5.9) 2 (15.4) 0 4 (6.0)
*Note: Not mutually exclusive as multiple responses possible.
doi:10.1371/journal.pone.0024035.t001
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centres and 30.8% of rural health clinics; none of the community
clinics used RDTs. Of the 4 facilities where RDTs were used in the
ANC clinic, 2 were rural health clinics and 2 were health centres;
none of the hospitals or community clinics used RDTs in the ANC
clinic.
Health worker survey
Health worker characteristics. Structured interviews were
conducted with 134 health workers working in the 67 public sector
antenatal clinics between August and December 2009. On average
two health workers were interviewed in each facility (ranging from
1 to 7). The vast majority of ANC personnel interviewed were
female (97.8%, 131/134). The median age of respondents was 48
years (IQR: 30–53 years). Half of the respondents were qualified
midwives or nurses (50.0%), followed by Community Health
Nurses (23.1%), or Nursing or Ward Assistants (22.4%). A
minority held other ranks, including orderly, traditional birth
attendant, nursing officer or public health nurse (4.5%). Almost
half of the respondents had been at the current facility for over 3
years; the proportion that had been in the ANC at the present
facility for over 3 years was slightly less at around 40% (Table 2).
Around 75% (98/134) of the respondents had attended a
workshop on malaria treatment or diagnosis; just over half of these
(54/98) were in the same year as the survey or during the previous
year. Almost 60% (78/134) of respondents had attended a
workshop specifically relating to malaria in pregnancy; 44.9% of
these within the last year and an additional 26.9% in the previous
year.
Knowledge of the consequences of malaria in
pregnancy. The health workers were asked their views on the
primary causes of anaemia, low birth weight and premature birth.
Malaria was the most frequently reported cause of maternal
anaemia (79.9%, 107/134), low birth weight (70.2%, 94/134) and
premature birth (82.1%, 110/134). Poor diet was also commonly
reported to contribute to the same health outcomes (82.1%, 60.5%
and 20.9% for maternal anaemia, low birth weight and premature
birth, respectively). Anaemia was reported to be an important
cause of low birth weight by 50.0% of respondents, and a cause of
premature delivery by 47.0%. Other responses on the cause of
maternal anaemia, low birth weight and premature delivery
included other infections such as sexually-transmitted infections or
worms (in the case of anaemia).
All respondents knew at least one consequence of malaria in
pregnancy for the mother and baby. The three most common
responses to specific questions on the consequences of malaria in
pregnancy for the baby were low birth weight (76.1%), premature
birth (47.8%) and death in utero/abortion (47.0%). For the mother,
the three most commonly reported consequences were anaemia
(72.4%), weakness (35.1%) and loss of appetite (29.1%); 28.4%
reported that the mother might die.
Knowledge of national policy for preventive treatment of
malaria in pregnancy (IPTp). Knowledge on most individual
components of the national policy for intermittent preventive
treatment of malaria in pregnancy was very high; for example only
one respondent could not name SP as the drug used for IPT and
did not know that women should receive three doses during
pregnancy. Ninety-two percent knew that the first dose should be
given after the first trimester, 97.8% knew that there should be a
minimum of one month between doses, and 96.3% reported that
SP-IPT should be administered as directly observed therapy
(DOT) (Table 3). When all of these components were combined,
88.1% (118/134) of ANC providers could correctly recall all of the
information requested.
The proportion of providers who knew the restrictions on the
use of SP-IPT was considerably lower: 52.2% could specify that
SP-IPT should not be given in the first trimester, and 54.5% that it
should not be given in the ninth month; no respondent suggested
existing treatment with cotrimoxazole as a contraindication
(Table 3). Combining all elements of the SP-IPT policy, including
restriction of SP use in the ninth month, 47.8% (64/134) of ANC
providers had full knowledge of SP-IPT administration; if the first
trimester timing restriction on the use of SP in pregnancy is also
included, then this falls to 15.7% (21/134).
Univariate log binomial regression was conducted to investigate
the predictors of ANC providers knowing all aspects of the SP-IPT
policy indicator, defined as the proportion who knew correct drug,
dose, timing and restrictions for SP-IPT (including ninth month
but excluding cotrimoxazole), and reported DOT. The first
trimester restriction was not included in the composite indicator as
this is already indirectly included by knowledge of the timing of
first SP-IPT dose.
Age, cadre, time at health facility and time in the present ANC
clinic showed no association with knowledge of the SP-IPT policy.
Those responsible for giving SP-IPT during ANC clinic days were
almost twice as likely to have full knowledge of the policy (RR:
1.90; 95% CI: 0.87,4.10; p = 0.10) (Table 4).
Recent attendance at a workshop on malaria diagnosis and
treatment or at a workshop on malaria in pregnancy (MiP)
increased the likelihood that the provider had full knowledge of
SP-IPT. For example those that attended a malaria diagnosis
workshop in 2007 or earlier were 0.60 times as likely to know
about SP-IPT than those who attended a workshop in 2009 (95%
Table 2. Health worker characteristics.
Variable N %
Age (years) 20–29 32 23.9
30–39 14 10.5
40–49 32 23.9
50 and above 56 41.8
Gender Female 131 97.8
Male 3 2.2
Cadre Midwife/Nurse 67 50.0
Nursing assistant 30 22.4
Community health nurse 31 23.1
Other 6 4.5
Time at current facility Less than 1 year 32 23.9
1–3 years 36 26.9
More than 3 years 66 49.3
Time in ANC at
current facility
Less than 1 year 38 28.4
1–3 years 40 29.9
4–9 years 40 29.9
10 years or longer 16 11.9
Responsible for dispensing
SP-IPT during ANC clinics
Yes 119 88.8
No 15 11.2
Responsible for prescriptions
during ANC clinics
Yes 118 88.1
No 16 11.9
doi:10.1371/journal.pone.0024035.t002
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Table 3. Health worker knowledge of policy for intermittent preventive treatment of malaria in pregnancy (IPTp) in Ashanti
Region, Ghana (N= 134 health workers).
Indicator N % 95% CI
Proportion who know that SP is correct drug for IPTp 133 99.3 94.7, 99.9
Proportion who know the correct timing of first dose of SP-IPT (after first trimester/16 weeks/quickening) 123 91.8 85.8, 95.4
Proportion who know pregnant women should receive 3 doses of SP-IPT 132 98.5 94.1, 99.6
Proportion who know there should be a minimum of 1 month between SP-IPT doses 131 97.8 93.2, 99.3
Proportion who reported SP-IPT should not be given in the first trimester 70 52.2 43.7, 60.6
Proportion who reported SP-IPT should not be given in the ninth month of pregnancy 73 54.5 45.7, 62.9
Proportion who know that SP-IPT should not be given if a woman is taking cotrimoxazole 0 0 -
Proportion reporting SP-IPT should be administered as directly observed treatment (DOT) 129 96.3 90.2, 98.6
Proportion who know correct drug, dose & timing for SP-IPT and report DOT 118 88.1 81.5, 92.5
Proportion who know correct drug, dose, timing & restriction for SP-IPT (including ninth month
but excluding first trimester & cotrimoxazole), and report DOT
64 47.8 39.0, 56.7
doi:10.1371/journal.pone.0024035.t003
Table 4. Univariate predictors of composite SP-IPT knowledge indicator (N = 134 health workers).
Knows full SP-IPT policy*
Predictor Sub-category % RR 95% CI P value
Age (years) 20–29 62.5 1.00 0.14
30–39 35.7 0.57 0.26,1.24
40–49 40.6 0.65 0.41,1.04
50 or older 46.4 0.74 0.51,1.09
Cadre Midwife/nurse 49.3 1.00 0.95
Nursing assistant 43.3 0.88 0.58,1.34
Community health nurse 48.4 0.98 0.64,1.51
Other 50.0 1.02 0.53,1.92
Time at health facility ,1 year 53.1 1.00 0.52
1–3 years 52.8 0.99 0.66,1.50
.3 years 42.4 0.80 0.52,1.23
Time in current ANC ,1 year 55.3 1.00 0.33
1–3 years 55.0 1.00 0.68,1.45
4–9 years 35.0 0.63 0.38,1.06
.10 years 43.8 0.79 0.44,1.44
Responsible for SP-IPT No 26.7 1.00 0.10
Yes 50.4 1.90 0.87,4.10
Attended malaria diagnosis workshop No 50.0 1.00 0.76
Yes 46.9 0.94 0.63,1.40
Year of malaria diagnosis workshop 2009 56.8 1.00 0.04
2008 58.8 1.04 0.61,1.75
2007 or before 34.1 0.60 0.36,1.00
Attended MiP workshop No 37.5 1.00 0.05
Yes 55.1 1.47 1.00,2.16
Year of MiP workshop 2009 57.1 1.00 0.05
2008 71.4 1.25 0.87,1.80
2007 or before 36.4 0.64 0.34,1.21
*Defined as the proportion that know the correct drug, dose, timing & restriction for SP-IPT (including ninth month but excluding first trimester and cotrimoxazole), and
report DOT.
doi:10.1371/journal.pone.0024035.t004
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CI: 0.36,1.00; p = 0.04); similarly, those who attended a MiP
workshop were approximately 1.5 times as likely to know about
SP-IPT than those who had not (RR: 1.47; 95% CI: 1.00,2.14;
p = 0.05); those who had attended a MiP workshop in 2007 were
0.64 times as likely to know about SP-IPT than those who
attended in 2009 (95% CI: 0.34,1.21; p = 0.05) (Table 4).
Given that none of the potential predictors of knowledge except
attendance of a MiP workshop were associated with the composite
knowledge indicator in the univariate regression, multivariate
modelling was not carried out.
Knowledge of national policy for treatment of uncom-
plicated malaria in pregnancy. When asked about the
recommended treatment for uncomplicated malaria in the first
trimester of pregnancy, only 50.8% (68/134) of ANC providers
correctly responded with quinine; 20.2% (27/134) responded with
artesunate-amodiaquine (AS–AQ), 14.2% (19/134) with artesunate
monotherapy and 7.5% (10/134) with SP. Even fewer could recall
the correct number of days (31.3%) or correct number of tablets
(29.9%) and how many times each day quinine should be
administered (33.6%); combining all of these individual elements
in to a composite indicator for knowledge of correct drug and dosing
regimen for treatment of uncomplicated malaria in the first
trimester, only 20.2% (27/134) of ANC providers demonstrated
full knowledge (Table 5).
The only factor significantly associated with provider knowledge
of correct quinine treatment during univariate log binomial
regression was attendance at a workshop on malaria in pregnancy
(RR: 2.51; 95% CI: 1.16,5.44; p= 0.02); the timing of this
workshop was not significant (Table 6).
When asked about the recommended treatment for uncomplicated
malaria in the second and third trimesters of pregnancy, 78.4% (105/
134) of providers correctly responded with the answer AS–AQ. More
detailed questions followed about the appropriate dose and duration of
AS–AQ treatment, regardless of whether the respondent had
responded with AS–AQ as the recommended drug. A high proportion
of providers could recall the correct duration and number of times AS–
AQ should be taken each day (89.6%, [120/134] and 93.3%, [120/
134], respectively). Knowledge of the correct number of AS and AQ
tablets was lower (64.9% and 50.7%, respectively).
Combining all of these individual elements in to a composite
indicator for correct drug and dosing regimen for treatment of
uncomplicated malaria in the second or third trimesters, only
41.8% (56/134) of ANC providers demonstrated full knowledge
(Table 5). The majority of respondents knew that AS–AQ should
not be given in the first trimester (73.9%, 99/134); when this
restriction was included with the full treatment indicator, 34.3%
(46/134) of ANC providers demonstrated full knowledge (Table 7).
Those responsible for writing prescriptions during ANC clinics
(RR: 2.98; 95% CI: 0.93,9.53; p= 0.06) and providers who had
attended a workshop on malaria in pregnancy (RR: 1.82; 95% CI:
1.02,3.24; p= 0.04) were more likely to know the correct treatment
regimen of AS–AQ in the second or third trimesters; timing of this
workshop was not significant (Table 6). No other variables were
significantly associated with correct knowledge of treatment for
uncomplicated malaria in the second or third trimesters. When
these two variables were included in a multivariate model,
workshop attendance retains borderline significance (RR: 1.70;
95% CI: 0.96,3.03; p = 0.07), whereas responsibility for prescrip-
tions is no longer significantly associated with knowledge of AS–
AQ treatment policy (RR: 2.64; 95% CI: 0.81,8.64; p= 0.11).
Qualitative key informant interviews
Experience & perceptions of anti-malarial drugs for
pregnant women. Overall, health worker perceptions on the
use of different anti-malarial drugs during pregnancy supports the
quantitative data in terms of believing that SP is for prevention
and that AS–AQ and quinine are for treatment:
‘‘I would prefer the use of SP as a preventive treatment but if the patient has
malaria, I would use the AS–AQ. The SP cannot treat malaria; it is only a
preventive treatment and it becomes more effective if the person sleeps under
insecticide treated nets and also, keep their environment clean.’’ (Interview
501, Senior Nursing Officer)
Side effects to both SP and AS–AQ were mentioned but most
ANC staff interviewed did not see these as inhibitory. For
example, they considered that the common adverse effects
associated with AS–AQ of weakness and dizziness can be avoided
by telling a woman to eat properly before she takes the drugs; most
reported reactions to SP relate to a woman being allergic to sulpha
containing drugs, in which case the health worker would change
the treatment. For example, in response to a question on how
pregnant women feel about AS–AQ:
‘‘Some complain of weakness the first time they take it so they rush here to
report that they feel weak. And we explain to them that, that is the nature of the
drug so if they take the drug and do not eat well, they will feel weak but even
then, the weakness lasts for just 2–3 days. They become alright if they are
taught the right way to take the drug.’’ (Interview 602, Nursing Assistant)
Chloroquine was spontaneously mentioned by a number of
those interviewed in relation to the treatment of malaria in
pregnancy with a preference for the current drugs (SP and AS–
AQ) due to fewer side effects in pregnant women; likewise side
effects and the long duration of the quinine treatment regimen
were given as justification for their preference for AS–AQ.
Use of RDTs by ANC staff. Many midwives expressed
support for the use of RDTs as these reduce reliance on
microscopy which can only be performed by trained personnel
and depends on electricity supply. Use of an RDT would also save
women from queuing for long periods of time at the laboratory.
‘‘It will be better for us to use this [RDT] than going to the lab because
there may be power cuts and unavailability of lab personnel in urgent situations
Table 5. Health worker knowledge of policy for treatment of uncomplicated malaria in the first trimester of pregnancy in Ashanti
Region, Ghana (N= 134).
Indicator N % 95% CI
Proportion who know quinine is the correct drug for malaria treatment in first trimester 68 50.7 39.8, 61.6
Proportion who know the correct number of days for quinine treatment (7 days) 42 31.3 22.4, 42.0
Proportion who know the correct number of times quinine should be taken each day (3 times) 45 33.6 24.0, 44.7
Proportion who know the correct number of 600 mg quinine tablets that should be taken each time (16600 mg) 40 29.9 21.7, 39.6
Proportion who know the correct dosing regimen of quinine to treat uncomplicated malaria during first trimester of pregnancy 27 20.1 13.2, 29.5
doi:10.1371/journal.pone.0024035.t005
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especially on weekends. It is faster and can be used by the midwife for rapid
results. It will also help the rural folks in their centres.’’ (Interview 301,
Midwife)
However, the almost universal negative consequence of the
introduction of RDTs in to routine ANC was perceived to be the
additional workload it would present, especially as free antenatal
care has seen the numbers attending ANC increase since its
introduction in July 2008.
On the other hand, the staff interviewed seemed motivated and
confident that they could use RDTs with appropriate training and
even if they did not receive support from additional staff then they
would find coping mechanisms as ultimately looking after the
pregnant women is their main objective. Task sharing between
midwives (and the laboratory and dispensary) in completing their
routine ANC activities already appears to be common. For
example, after an initial health education talk for all attendees,
ANC clinics in a number of facilities are arranged in to ‘‘stations’’
which each woman passes through to receive services such as
palpation, blood pressure and weight measurements, history
taking, IPTp and PMTCT. If RDTs were introduced then a
number of respondents suggested that they could be incorporated
in to this system:
‘‘The problem we face here is that the midwives are few but if more
midwives are trained... Personally if it is fused with my work it won’t be a
problem because wherever the pregnant woman finds herself the midwife will be
there to help her and there wouldn’t be a problem of maternal death or
premature delivery or even abortion. For me, it is good.’’ (Interview 102,
Midwife)
‘‘Division of labour... If we are many it will help us. If we are all trained in
taking the samples so that whilst one [of us] is taking care of one [mother],
another [of us] is taking care of another [mother]’’ (Interview 203,
Midwife)
Acceptability of IST versus SP-IPT. The general view of the
midwives is that whatever misgivings pregnant women might have
Table 6. Univariate predictors of composite first trimester malaria treatment, and second/third trimester malaria treatment
knowledge indicators (N = 134 health workers).
Knows full malaria treatment
policy for 1st trimester*
Knows full malaria treatment
policy for 2nd & 3rd trimesters**
Predictor Sub-category % RR 95% CI P value % RR 95% CI P value
Age (years) 20–29 6.3 1.00 0.15 28.1 1.00 0.27
30–39 21.4 3.43 0.89,13.2 42.9 1.52 0.66,3.51
40–49 31.3 5.00 1.19,21.0 25.0 0.89 0.44,1.79
50 or older 21.4 3.43 0.84,14.1 41.1 1.46 0.87,2.46
Cadre Midwife/nurse 26.9 1.00 0.24 40.3 1.00 0.55
Nursing assistant 20.0 0.74 0.25,2.14 26.7 0.66 0.33,1.31
Community health nurse 9.7 0.36 0.11,1.18 29.0 0.72 0.39,1.34
Other 0 - - 33.3 0.83 0.34,2.00
Time at health facility ,1 year 21.9 1.00 0.16 34.4 1.00 0.95
1–3 years 8.3 0.38 0.11,1.29 36.1 1.05 0.54,2.03
.3 years 25.8 1.18 0.55,2.53 33.3 0.97 0.51,1.86
Time in current ANC ,1 year 18.4 1.00 0.35 36.8 1.00 0.96
1–3 years 12.5 0.68 0.22, 2.06 32.5 0.88 0.49,1.58
4–9 years 27.5 1.49 0.68,3.29 32.5 0.88 0.45,1.73
.10 years 25.0 1.36 0.49,3.79 37.5 1.02 0.46,2.24
Responsible for prescriptions No 12.5 1.00 0.46 12.5 1.00 0.06
Yes 21.2 1.69 0.41,6.94 37.3 2.98 0.93,9.53
Attended malaria diagnosis
workshop
No 11.1 1.00 0.11 25.0 1.00 0.18
Yes 23.5 2.11 0.85,5.25 37.8 1.51 0.83,2.76
Year of malaria diagnosis
workshop
2009 29.7 1.00 0.55 48.6 1.00 0.16
2008 23.5 0.79 0.30,2.06 35.3 0.73 0.33,1.58
2007 or before 18.2 0.61 0.25,1.48 29.5 0.61 0.36,1.02
Attended MiP workshop No 10.7 1.00 0.02 23.2 1.00 0.04
Yes 26.9 2.51 1.16,5.44 42.3 1.82 1.02,3.24
Year of MiP workshop 2009 31.4 1.00 0.59 42.9 1.00 0.48
2008 28.6 0.91 0.37,2.23 52.4 1.22 0.64,2.32
2007 or before 18.2 0.58 0.20,1.71 31.8 0.74 0.34,1.62
*Defined as the proportion that know the correct drug, dose and duration; not including restrictions to using quinine in 1st trimester only for uncomplicated malaria.
**Defined as the proportion that know the correct drug, dose & duration to treat uncomplicated malaria during second/third trimesters of pregnancy, including
restrictions on use of AS–AQ during first trimester.
doi:10.1371/journal.pone.0024035.t006
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about either the drugs or repeat blood tests, they can be overcome
by explaining and educating them that it is for the health of
themselves and their babies.
It is also generally accepted that, regardless of opinions or
experiences of pregnant women suffering adverse effects, SP is for
prevention and AS–AQ is for treatment. However, perhaps
reflecting on the nature of the role of ANC providers, when the
IST strategy was summarised and they were directly asked which
strategy they would prefer between IST and SP-IPT, more tended
to favour SP-IPT stating the old adage that ‘‘prevention is better
than cure’’:
‘‘Fansidar [SP] is for preventive purposes. It is not used for treatment. It is
the AS–AQ that is used to treat malaria. But because prevention is better than
cure, I prefer the use of Fansidar for prevention.’’ (Interview 302, Midwife)
This was not a universal view however, with a small number of
midwives interviewed stating that they would prefer to test women
to be sure that they had malaria before giving them ‘‘strong’’ drugs
such as AS–AQ unnecessarily, and to make sure that they did not
miss any other diagnosis.
‘‘You see no-one likes taking drugs and with these pregnant women, I think
some of them are not even taking their routine drugs... The SP is for prevention,
the person may ask why she should take it when she doesn’t have the MPs
[malaria parasites]... Personally, I prefer the AS–AQ. The blood should be
tested and if the woman has the MPs she will be given the AS–AQ’’
(Interview 102, Midwife)
‘‘The AS–AQ is best for treatment. But I will only give the AS–AQ out if
she has been diagnosed at the lab for MPs [malaria parasites].’’ (Interview
201, Midwife)
It should be noted that some of the responses to this question
suggest that not all of the interviewees fully understood the IST
approach, despite working in facilities where the trial had taken
place; they expressed concern that some women present too late
with symptoms of malaria for effective treatment, hence their
preference for ‘‘prophylactic’’ treatment with SP.
Discussion
The quantitative and qualitative data presented here support
the view that malaria is perceived as a serious problem for
pregnant women in the Ashanti Region of Ghana.
Knowledge of most of the key components of the IPTp policy is
extremely good with over 95% knowing that SP is the
recommended drug, that women should receive three doses
during their pregnancy, with an interval of a month between
doses, and that SP-IPT should be given as directly observed
therapy (DOT); 92% also knew that the first dose should be given
after 16 weeks or quickening. Knowledge of the restrictions
around the use of SP for IPT is less strong. For example, only
around 50% could recall that SP-IPT should not be given in the
first trimester, or ninth month. However, since most respondents
knew the correct time to start SP-IPT, it is possible that this
question was not fully understood, or perhaps the ANC personnel
interviewed are not aware that the reason for timing of SP-IPT
doses is due to the potential adverse consequences of taking SP in
the first trimester of pregnancy. None of the respondents reported
that SP-IPT is contraindicated if a woman is taking daily
cotrimoxazole prophylaxis to prevent HIV-related opportunistic
infections; this perhaps relates to the low HIV prevalence of 3.6%
amongst pregnant women in Ghana [18] meaning that few
pregnant women are likely to be taking prophylactic cotrimox-
azole and so health worker experience of this is low.
Knowledge of the SP-IPT policy was stronger than that of the
malaria treatment policies for pregnant women, particularly
treatment with quinine for uncomplicated malaria in the first
trimester. Knowledge of the timing restrictions for giving quinine
for uncomplicated malaria was poor; in the case of AS–AQ, a
bigger problem was in reporting the appropriate AQ dose.
Findings from the qualitative study suggest this may be due to
experience of adverse effects of AQ which leads to health workers
giving lower doses (rather than not knowing the correct dose per se);
health worker mistrust of AQ has been demonstrated elsewhere
[19], although overall the respondents in this study in Ashanti
Region observed that AS–AQ was effective in treating pregnant
women with malaria and considered it to be generally acceptable,
despite side effects in some women.
Lack of clarity around the timing and restrictions on the use of
quinine for uncomplicated malaria may relate to the low numbers
of women seen at ANC in their first trimester; in addition, quinine
is also the recommended treatment for complicated malaria at any
gestation. However, this lack of knowledge may simply be due to
the fact that ANC staff in the majority of facilities in this study do
not have responsibility for dispensing anti-malarial treatment;
although 88% of respondents reported that they were responsible
for writing prescriptions during ANC clinics, only 25% of facilities
had AS–AQ available in their ANC department for dispensing by
Table 7. Health worker knowledge of policy for treatment of uncomplicated malaria in the second and third trimesters of
pregnancy in Ashanti Region, Ghana (N= 134).
Indicator N % 95% CI
Proportion who know that artesunate-amodiaquine (AS–AQ) is the correct drug for malaria treatment in second/third trimesters* 105 78.4 70.7, 84.5
Proportion who know that AS–AQ treatment should be given for 3 days* 120 89.6 81.2, 94.5
Proportion who know AS–AQ should be taken 2 times each day* 125 93.3 85.4, 97.1
Proportion who know that 2 artesunate (AS) tablets should be taken each time 87 64.9 55.3, 73.5
Proportion who know 2 amodiaquine (AQ) tablets should be taken each time 68 50.7 41.4, 60.1
Proportion who know 2AS and 2AQ tablets should be taken each time 66 49.3 39.8, 58.8
Proportion who reported AS–AQ should not be given in the first trimester 99 73.9 64.9, 81.3
Proportion who know the correct drug, dose & duration to treat uncomplicated malaria during second/third trimesters of pregnancy 56 41.8 32.2, 52.0
Proportion who know the correct drug, dose & duration to treat uncomplicated malaria during second/third trimesters of pregnancy,
including restrictions on use of AS–AQ during the first trimester.
46 34.3 25.7, 44.1
*Note: the proportion of ANC staff that could report the correct duration of treatment with AS–AQ was higher than those that reported AS–AQ as the first-line drug for
treatment of uncomplicated malaria in pregnancy; this is because questions on dose and duration of AS–AQ treatment for a pregnant woman in her second or third
trimester were asked to all respondents, irrespective of their answer to the most appropriate drug.
doi:10.1371/journal.pone.0024035.t007
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midwives, compared to the 70% that had SP available for
dispensing by midwives. Quinine dispensing in the ANC was not
specifically investigated. Responsibility for giving SP-IPT during
ANC was a predictor of borderline statistical significance of full
knowledge of SP-IPT policy; similarly for AS–AQ, those
responsible for prescriptions during ANC were more likely to
know the full second and third trimester treatment indicator. This
was not the case for quinine; the reason for the discrepancy
between AS–AQ and quinine is not clear. The qualitative analysis
found that ANC staff may send pregnant women with suspected
malaria for diagnostic tests and write a prescription for an anti-
malarial if they have a confirmed diagnosis. However, the details
of drug and dosage are the responsibility of dispensary staff.
Perhaps personal experience of AS–AQ treatment compared to
quinine is responsible for better knowledge of the treatment
regimen.
The main predictor for success with all three knowledge
indicators was attendance at a workshop on malaria in pregnancy.
For the SP-IPT composite indicator, recent training was a factor,
whereas for knowledge of treatment with quinine in the first
trimester and AS–AQ in the second/third trimesters the timing of
the workshop was not important. Unfortunately since the sampling
unit was health facilities and there is likely to be some clustering on
the knowledge outcomes within health facilities, the study was not
powered to explore the multivariate effect of the potential
predictors of knowledge. Nevertheless, the findings presented here
suggest that training can be effective in improving knowledge of
ANC staff on certain aspects of malaria such as the consequences
of malaria for the pregnant woman and her baby, preventive
measures and (to some extent) treatment. However, malaria
treatment practice was not observed as part of the current study
and although correct knowledge is essential it is not sufficient to
assume translation to appropriate behaviour; indeed, several
studies in different settings have shown quality of malaria case
management is not significantly influenced by in-service training
or guidelines [20,21,22,23].
Similarly, despite the high knowledge of SP-IPT policy
described here, the 2008 Ghana demographic and health survey
(DHS) found that only 50.8% of women in Ashanti Region with a
live birth in the preceding two years had received two or more
doses of SP-IPT [12]. Routine data from the health facilities in this
study show medians of 63%, 41% and 20% of ANC registrants in
2008 receiving one, two and three doses of SP-IPT, respectively.
Low coverage of SP-IPT, especially the second and third doses is
known to be of concern to the district and regional health
authorities in Ashanti Region with late attendance by pregnant
women often blamed for this. However, it is unlikely that this is the
only reason for low SP-IPT coverage. For example, 21.3% (10/47)
of the ANC clinics in this study which dispensed SP reported stock
outs in the 6 months before the survey, in part attributed to delays
in reimbursement of facilities that provide free ANC through the
national health insurance scheme; additionally, only 58.2% (39/
67) always had water freely available for DOT, matching
challenges to SP-IPT implementation described for other settings
[24,25,26].
The relatively low coverage of SP-IPT in Ashanti Region,
despite the strong knowledge and acceptance of the strategy by
health workers, supports the need for operational research to
identify areas of weakness within the health system that need
targeting by interventions. This is particularly relevant when
considering introducing a new strategy. For example, if rising SP
resistance means that SP-IPT is no longer effective, intermittent
screening and treatment may be considered for roll-out as an
alternative approach for MiP control. Maintaining stock of RDTs
and AS–AQ will be vital if the efficacy of IST found under trial
conditions is to translate to similar levels of effectiveness under
operational conditions.
A key question is whether midwives would be able to deliver
IST in the ANC. The first essential of IST is effective diagnosis of
malaria. Microscopy services are available in 40% of all facilities in
Ashanti but only around 20% of the lower level facilities have
microscopes or conduct malaria blood slides. Therefore, if IST
were to be introduced as a MiP intervention with diagnosis
undertaken in the ANC, this would have to rely on RDTs.
The situation with regard to dispensing of anti-malarials is less
clear. The vast majority (91.0%) of facilities have a dispensary and
although there is some dispensing of drugs in other departments
such as on the wards of hospitals and health centres, and in the
ANC clinics, 30% of facilities do not keep SP in their ANC clinics
for dispensing by midwives and almost 75% do not keep AS–AQ
in the ANC. Therefore, it is uncertain whether women found to
have malaria whilst attending an ANC clinic should be treated in
the ANC or whether the woman should be sent with a prescription
to the dispensary.
Other potential barriers to a change in strategy if it were to be
implemented by ANC providers is the strong emphasis on
prevention versus treatment amongst the midwives, reflecting
their role as primary health care agents, and the worry about
increased workload if they are expected to use RDTs and dispense
ACT during ANC clinics. The concern of certain providers that
some women present too late with symptoms of malaria for
effective treatment underscored their preference for ‘‘prophylac-
tic’’ treatment with SP. However, the principle of intermittent
screening and treatment is that women would be tested with an
RDT at key scheduled ANC visits, regardless of whether they
reported malaria symptoms, so that asymptomatic malaria would
also be identified and treated early. This misconception suggests
that if IST were to be introduced, the details of the strategy would
need to be very clearly explained to avoid resistance to the idea of
treatment versus prevention. Nevertheless, the in-depth interviews
with providers in the trial facilities revealed that there was little
direct opposition to the IST strategy and many of the midwives
related other stories of evidence influencing practice such as the
change of malaria treatment policy from chloroquine to SP and
then AS–AQ due to increasing drug resistance. This suggests that
if research shows that SP is beginning to fail for use as IPT then an
alternative strategy such as IST may be accepted, particularly if
coupled with promotion of ITN use following the Ashanti IST trial
protocol [6].
Similarly, it is likely that increased workload may not be as
significant a barrier as the health workers suggest [27] with
demonstrated task sharing and team work being important
elements of day-to-day operation in the Ashanti Region health
facilities surveyed. The main motivation of the health workers
interviewed in-depth was the well being of the pregnant women
under their care.
ANC staff already carry out a diverse range of tasks: they test for
HIV, syphilis and urine protein using point-of-care devices. There
is currently a strong advocacy for using point-of-care devices in
health facilities for diagnosis. So another question now emerging is
whether IST should be a stand-alone strategy for control of
malaria in pregnancy or whether screening for other infections in
pregnancy, such as sexually transmitted infections, could be linked
to it.
In terms of delivering IST, the general view of the midwives is
that whatever misgivings the pregnant women might have about
either the drugs or repeat blood tests, they can be overcome by
explaining and educating them that it is for the health of
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themselves and their babies. Interestingly, this correlates well with
the findings of focus group discussions with mothers involved in
the Ashanti IST trial for whom trust of ANC staff was found to be
a more critical factor in the acceptance of either strategy than any
particular characteristics of the strategies themselves [10]. Hence
health worker support for any malaria in pregnancy intervention
delivered through ANC is critical.
Cost effectiveness is an important element for decision-making
in terms of any future policy change. In the case of IST this relates
to both deciding whether to introduce the IST approach in place
of SP-IPT, and also to the most efficient way that this strategy
could be implemented. Economic modelling would be useful in
determining whether the IST strategy is more cost effective as an
ANC-based intervention in lower level facilities which do not have
malaria microscopy when compared to hospitals. Costs data were
collected alongside the original Ashanti IST trial and a cost
effectiveness evaluation is currently being finalised and prepared
for publication which will add further information to the debate
for policy makers considering future options for MiP interventions.
Further information on the costs of IST is being collected during
the course of the multicentre trial currently underway in four
countries in West Africa.
One potential limitation of this study is that the qualitative data
are from facilities involved in the Ashanti IST trial. However,
these two districts were purposefully not selected in the
quantitative study. It is therefore possible that the in-depth
opinions given by health workers in these two trial districts may be
different to those who took part in the questionnaire survey.
However, the two sources of data were intended to be
complementary i.e. the quantitative data on MiP knowledge is
representative of the majority of ANC providers in Ashanti region,
whereas qualitative data on the potential barriers or facilitators to
implementation of IST is drawn from providers with some
exposure to the intervention and how it might fit with their usual
responsibilities. Nevertheless, ANC providers in the qualitative
study were not directly involved in delivering the trial interven-
tions and their strength of opinion on the status quo suggests their
knowledge and perceptions had not been very noticeably changed
by the presence of the project team in their facilities so that it is not
unreasonable to draw the two sources of data together.
Conclusion. If IST was considered by policy makers to be a
viable and necessary alternative to SP-IPT and that it should be
introduced and implemented as part of routine ANC activities,
considerable attention would need to be paid to improving the
knowledge and practices of ANC staff in relation to appropriate
treatment of confirmed malaria in pregnancy. Similarly, it is
possible that the strong belief in preventive measures such as IPTp
and ITNs for malaria in pregnancy control may be an inhibitory
factor for some ANC staff in shifting from IPTp to IST. However,
this appears to reflect the effectiveness of MoH emphasis and
training on preventive interventions and if similar attention were
given to the IST strategy it may also see similar impact in terms of
provider knowledge. In addition to improving health system
factors such as a reliable supply chain, gaining the confidence and
support of health workers that provide ANC services and deliver
malaria interventions to pregnant women would be critical for
successful implementation.
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